Lipocine Inc. (LPCN) Stock Price & Analysis
Lipocine Inc. (LPCN) rose 1.24% to USD 2.45 as of September 8, 2026 at 10:18 UTC, according to Nexqual real-time market data.
LPCN last closed at USD 2.45; the session ranged USD 2.36–2.48 on volume of 23,181 shares. Market capitalization is —, with a 52-week range of USD 1.81–12.37 (NCM). Source: Nexqual, September 8, 2026 at 10:18 UTC.
Key Statistics (as of September 8, 2026 at 10:18 UTC)
| Price | USD 2.45 |
|---|---|
| Change | ▲ 1.24% (up) |
| Previous Close | USD 2.45 |
| Open | USD 2.45 |
| Day Range | USD 2.36 – 2.48 |
| 52-Week Range | USD 1.81 – 12.37 |
| Volume | 23,181 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (LPCN)
Nexqual's technical model rates LPCN "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 10:18 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.03 (overbought) |
| vs SMA50 | Above (USD 2.23) |
| MACD | 0.05 (positive) |
From Lipocine Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- In 2025 and 2024, we spent $8.6 million and $7.4 million, respectively, on research and development.   Competition   Neuroactive Steroids Market overview   The unique potential mechanism of action ("MOA") of NAS presents an opportunity to treat a variety of CNS disorders.
- Our proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options.
- We will also continue efforts to enter into partnership arrangements for the continued development and/or marketing of LPCN 1144, LPCN 1148, LPCN 2401, LPCN 1107 as well as for the TRT Assets outside of the Currently Licensed TLANDO Territories.   Our products are based on our proprietary drug delivery technology platform.
- We intend to focus on the development of endogenous neuroactive steroids ("NASs") which have broad applicability in treating various CNS conditions where we can leverage our technology platform to develop highly differentiated oral therapeutics.
Partnerships
- On January 31, 2024, our license agreement with the former licensee (the "Antares License Agreement"), Antares Pharma, Inc. ("Antares"), was terminated and the transition of the U.S. commercial rights for TLANDO from Antares to Verity was completed on February 1, 2024, for the distribution, marketing and sale of TLANDO.
- We are also eligible to receive milestone payments of up to $259 million in the aggregate, depending on the achievement of certain sales milestones in a single calendar year and/or development milestones with respect to products licensed by Verity under the Verity License Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DARE | Dare Bioscience, Inc. | USD 0.72 | ▼ 2.57% |
| FBIO | Fortress Biotech, Inc. | USD 2.72 | ▼ 0.37% |
| SCYX | SCYNEXIS, Inc. | USD 5.3 | ▲ 1.53% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.37 | ▼ 2.47% |
| VTGN | VistaGen Therapeutics, Inc. | USD 0.24 | ▼ 2.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:18 UTC. This page is informational and not investment advice.